1. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.
- Author
-
Graber JJ, Ford D, Zhan M, Francis G, Panitch H, and Dhib-Jalbut S
- Subjects
- Dose-Response Relationship, Drug, Drug Resistance, Humans, Interferon-gamma analysis, Interferon-gamma drug effects, Interleukin-10 analysis, Interleukin-12 analysis, Interleukin-12 biosynthesis, Interleukin-12 Subunit p40 analysis, Interleukin-12 Subunit p40 drug effects, Magnetic Resonance Imaging, Multiple Sclerosis blood, Multiple Sclerosis pathology, Immunologic Factors administration & dosage, Interferon-beta administration & dosage, Interleukin-10 biosynthesis, Multiple Sclerosis drug therapy
- Abstract
We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 microg intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 microg subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p<0.01) levels and the ratios of cellular IL-10/IL-12p40 (p<0.01) and IL-10/IL-12p70 (p<0.02) while cellular IFN-gamma levels were reduced (p<0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p<0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p=0.031) and a decrease in cellular IL-12p70 (p<0.02). A decrease in cellular IFN-gamma was observed in responders (p=0.013). This is the first study that compares cytokine changes between the two IFN-beta regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.
- Published
- 2007
- Full Text
- View/download PDF